Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Media sera and Reagents- Cell culture Companies

Media, sera, and reagents for cell culture are essential components in the field of biotechnology and life sciences. These products are crucial for the growth, maintenance, and experimentation with cells in vitro. Various companies are involved in the production and distribution of media, sera, and reagents for cell culture.

Media Sera and Reagents- Cell Culture Key Companies

Latest Media Sera and Reagents Companies Update

Oct 2023: A new business partnership between Vaxcyte and Lonza pertains to the worldwide production of broad-spectrum pneumococcal conjugate vaccines (PCVs). The new agreement, which builds on an earlier partnership, will allow Vaxcyte's PCV candidates, VAX-24 and VAX-31, to be commercialized globally for adult and pediatric populations. This arrangement backs Vaxcyte's plan to use Lonza's current infrastructure for clinical research and the impending adult VAX-24 launch in the US. Vaxcyte will have access to a specially designed manufacturing suite from Lonza as part of its Ibex Dedicate Biopark at its Visp, Switzerland, location. The suite will be utilized to create necessary parts for the PCV franchise owned by Vaxcyte. With VAX-24 nearing late-stage clinical studies, Vaxcyte's production facility will assist in meeting the long-term worldwide market demands for adults and children.

May 2023: Merck Life Science, a pharmaceutical firm, and the Department of Atomic Energy partnered to provide heavy water for five years. According to an official announcement, a deal between Merck's sister company Sigma Aldrich Chemicals and Heavy DAE's Heavy Water Board will allow for manufacturing of deuterium-labeled compounds (DLCs) and related value-added products. Private companies' local manufacture of DLCs will increase India's exports.

List of Media Sera and Reagents Key companies in the market

PAN biotech(Germany)

Sigma Aldrich (US)

Thermofisher Scientific (US)

General electric company (US)

Biowest (France)

Merck KGaA (Germany)

Lonza AG (Switzerland)

Hi-media Laboratories (India)

VWR International

PromoCell GmbH

Media sera and Reagents- Cell culture Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.